Presentations and Publications

Reneo Pharmaceuticals Research

Predictive Physiologically Based Pharmacokinetic (PBPK) Model Suggests Minimal Drug-Drug Interaction (DDI) Between PPARδ Agonist Mavodelpar (REN001) & Rosuvastatin

Emery et al., ACCP Annual Meeting, Bellevue, WA

Click to view

Mavodelpar Clinical Development Program in Adult Patients with Primary Mitochondrial Myopathies: Results from a Phase 1b Study and Design of Ongoing Pivotal Study (STRIDE)

Dr Rob Pitceathly - SSIEM conference presentation Weds 30th August, 2023, 9.30am

Click to view

Reneo Pharmaceuticals Clinical Trial Update Presentation

Alejandro Dorenbaum, MD - UMDF June 30, 2023

Click to view

PPARδ Agonist Mavodelpar (REN001) Improves Mitochondrial Function in Skeletal Muscle: an Investigational Treatment for Primary Mitochondrial Myopathies*

Adams et al., UMDF 2023

Click to view

Clinical Manifestations and Disease Burden of Primary Mitochondrial Myopathies (PMM): Results from a Patient Journey Analysis Shows Substantial Healthcare Resource Utilization

Sirimanne et al., UMDF 2023

Click to view